Olema Pharmaceuticals, INC 10-Q quarterly reports

Olema Pharmaceuticals reported a significant increase in operating expenses, leading to a wider net loss for the period, despite continued progress in its clinical development programs.

Olema Pharmaceuticals has entered into a lease agreement for a new corporate headquarters in South San Francisco, California.

Olema Pharmaceuticals reports a significant increase in net losses for Q3 and the first nine months of 2025, driven by expanded R&D for its breast cancer pipeline, while maintaining sufficient liquidity for the next 12 months.

Olema Pharmaceuticals progresses its lead breast cancer therapies through late-stage trials while reporting increased R&D expenses and net losses in Q2 2025.

Olema Pharmaceuticals reports its financial results for the first quarter of 2025, highlighting progress in clinical trials and strategic collaborations.

Olema Pharmaceuticals reports a net loss of $34.6 million for the third quarter of 2024, alongside updates on clinical trials and financial status.

Olema Pharmaceuticals reports a net loss of $30.4 million for the second quarter of 2024, while advancing its clinical programs and securing additional financing.

Olema Pharmaceuticals reported a net loss of $30.97 million for the first quarter of 2024, while highlighting progress in clinical trials and pipeline development.